PCN92 INOTUZUMAB OZOGAMICIN VERSUS STANDARD CHEMOTHERAPY...

Value in Health 2019 / 05 Vol. 22

PCN92 INOTUZUMAB OZOGAMICIN VERSUS STANDARD CHEMOTHERAPY FOR RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A COST-UTILITY ANALYSIS FROM THE PERSPECTIVE OF NATIONAL HEALTH INSURANCE ADMINISTRATION IN TAIWAN

Lee, T.Y., Chen, T.Y., Li, S.S., Lo, Y.W., Wen, Y.C., Ou, H.T.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
22
Language:
english
Journal:
Value in Health
DOI:
10.1016/j.jval.2019.04.216
Date:
May, 2019
File:
PDF, 381 KB
english, 2019
Conversion to is in progress
Conversion to is failed